# Study of Donepezil in Female Breast Cancer Survivors With Cognitive Dysfunction

> **NCT01466270** · PHASE2 · COMPLETED · sponsor: **Wake Forest University Health Sciences** · enrollment: 62 (actual)

## Conditions studied

- Anxiety Disorder
- Breast Cancer
- Cognition Disorders
- Depression
- Fatigue
- Sleep Disorders

## Interventions

- **DRUG:** donepezil hydrochloride
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01466270
- **Lead sponsor:** Wake Forest University Health Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07
- **Primary completion:** 2013-10-01
- **Final completion:** 2013-10-01
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2021-10-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01466270

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01466270, "Study of Donepezil in Female Breast Cancer Survivors With Cognitive Dysfunction". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01466270. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*